Abstract
Many studies have pointed out the role of 18F-FDG PET/CT (or 18F-FDG PET) in patients with clinical stage III or II breast cancer. 18F-FDG PET/CT might advantageously replace other staging procedures, such as bone scanning and possibly contrast-enhanced CT of the thorax or abdomen–pelvis. We discuss the findings, locoregional or distant, that can be expected in different categories of breast cancer and their impact on prognosis and management. We also discuss the role of 18F-FDG PET/CT in restaging and how 18F-FDG PET/CT compares with conventional techniques in restaging for patients with suspected disease recurrence. We conclude with some recommendations for clinical practice and future research.
- © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.